Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.
<h4>Background</h4>Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19). In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up.<h4>Methods</h4>In a registry-stu...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0252388 |
id |
doaj-356730e1848248f3bd72a4961f956a74 |
---|---|
record_format |
Article |
spelling |
doaj-356730e1848248f3bd72a4961f956a742021-07-11T04:30:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01166e025238810.1371/journal.pone.0252388Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.Anis SaibWalid AmaraPascal WangSimon CattanAzeddine DellalKais RegaiegStephane NahonOlivier NalletLee S Nguyen<h4>Background</h4>Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19). In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up.<h4>Methods</h4>In a registry-study which included patients hospitalized for COVID-19 between March 15 and April 2, 2020, we compared patients who received HCQ/AZI to those who did not, regarding a composite outcome of mortality and mechanical ventilation with a 28-days follow-up. QT was monitored for patients treated with HCQ/AZI. Were excluded patients in intensive care units, palliative care and ventilated within 24 hours of admission. Three analyses were performed to adjust for selection bias: propensity score matching, multivariable survival, and inverse probability score weighting (IPSW) analyses.<h4>Results</h4>Overall, 203 patients were included: 60 patients treated by HCQ/AZI and 143 control patients. During the 28-days follow-up, 32 (16.3%) patients presented the primary outcome and 23 (12.3%) patients died. Propensity-score matching identified 52 unique pairs of patients with similar characteristics. In the matched cohort (n = 104), HCQ/AZI was not associated with the primary composite outcome (log-rank p-value = 0.16). In the overall cohort (n = 203), survival and IPSW analyses also found no benefit from HCQ/AZI. In the HCQ/AZI group, 11 (18.3%) patients prolonged QT interval duration, requiring treatment cessation.<h4>Conclusions</h4>HCQ/AZI combination therapy was not associated with lower in-hospital mortality and mechanical ventilation rate, with a 28-days follow-up. In the HCQ/AZI group, 18.3% of patients presented a prolonged QT interval requiring treatment cessation, however, control group was not monitored for this adverse event, making comparison impossible.https://doi.org/10.1371/journal.pone.0252388 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anis Saib Walid Amara Pascal Wang Simon Cattan Azeddine Dellal Kais Regaieg Stephane Nahon Olivier Nallet Lee S Nguyen |
spellingShingle |
Anis Saib Walid Amara Pascal Wang Simon Cattan Azeddine Dellal Kais Regaieg Stephane Nahon Olivier Nallet Lee S Nguyen Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. PLoS ONE |
author_facet |
Anis Saib Walid Amara Pascal Wang Simon Cattan Azeddine Dellal Kais Regaieg Stephane Nahon Olivier Nallet Lee S Nguyen |
author_sort |
Anis Saib |
title |
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. |
title_short |
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. |
title_full |
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. |
title_fullStr |
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. |
title_full_unstemmed |
Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. |
title_sort |
lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for covid-19 pneumonia: a retrospective study. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2021-01-01 |
description |
<h4>Background</h4>Hydroxychloroquine combined with azithromycin (HCQ/AZI) has initially been used against coronavirus disease-2019 (COVID-19). In this retrospective study, we assessed the clinical effects of HCQ/AZI, with a 28-days follow-up.<h4>Methods</h4>In a registry-study which included patients hospitalized for COVID-19 between March 15 and April 2, 2020, we compared patients who received HCQ/AZI to those who did not, regarding a composite outcome of mortality and mechanical ventilation with a 28-days follow-up. QT was monitored for patients treated with HCQ/AZI. Were excluded patients in intensive care units, palliative care and ventilated within 24 hours of admission. Three analyses were performed to adjust for selection bias: propensity score matching, multivariable survival, and inverse probability score weighting (IPSW) analyses.<h4>Results</h4>Overall, 203 patients were included: 60 patients treated by HCQ/AZI and 143 control patients. During the 28-days follow-up, 32 (16.3%) patients presented the primary outcome and 23 (12.3%) patients died. Propensity-score matching identified 52 unique pairs of patients with similar characteristics. In the matched cohort (n = 104), HCQ/AZI was not associated with the primary composite outcome (log-rank p-value = 0.16). In the overall cohort (n = 203), survival and IPSW analyses also found no benefit from HCQ/AZI. In the HCQ/AZI group, 11 (18.3%) patients prolonged QT interval duration, requiring treatment cessation.<h4>Conclusions</h4>HCQ/AZI combination therapy was not associated with lower in-hospital mortality and mechanical ventilation rate, with a 28-days follow-up. In the HCQ/AZI group, 18.3% of patients presented a prolonged QT interval requiring treatment cessation, however, control group was not monitored for this adverse event, making comparison impossible. |
url |
https://doi.org/10.1371/journal.pone.0252388 |
work_keys_str_mv |
AT anissaib lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT walidamara lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT pascalwang lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT simoncattan lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT azeddinedellal lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT kaisregaieg lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT stephanenahon lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT oliviernallet lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy AT leesnguyen lackofefficacyofhydroxychloroquineandazithromycininpatientshospitalizedforcovid19pneumoniaaretrospectivestudy |
_version_ |
1721309430946988032 |